22 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 18 Phase 2, 16 Phase 1, 5 Phase 3, 1 Phase 4.
Follow Pralatrexate: new trials by email Literature Review of Pralatrexate trials Research Report on Pralatrexate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Romidepsin, Pralatrexate - Lymphoma, T-Cell, Peripheral | Phase 3 | Withdrawn | Jennifer Amengual | 2018-09-01 | 2018-12-19 | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma Pralatrexate - Relapsed or Refractory Peripheral T-cell Lymphoma | Completed | Samsung Medical Center | 33 | 2016-09-23 | 2017-11-29 | |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Pralatrexate - Peripheral T Cell Lymphoma, Progression, Disease | Phase 4 | Unknown | Taiwan Mundipharma Pharmaceuticals Ltd. | 22 | 2016-08-30 | 2017-05-12 |
| A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL pralatrexate, Vitamin B12 and folic acid - Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 3 | Completed | Mundipharma (China) Pharmaceutical Co. Ltd | 85 | 2015-09-10 | 2019-10-01 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Pralatrexate, Romidepsin - Lymphoid Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 57 | 2013-09-09 | 2026-09-16 |
| Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® Folotyn, Fusilev - Non-Small Cell Lung Cancer | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-04-01 | 2020-01-23 | |
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Alisertib, Pralatrexate, Gemcitabine - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 271 | 2012-06-11 | 2018-07-31 |
| KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) KW-0761, Pralatrexate, gemcitabine plus oxaliplatin - Adult T-cell Leukemia-Lymphoma | Phase 2 | Completed | Kyowa Kirin, Inc. | 71 | 2012-06-01 | 2024-04-25 |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies Erlotinib, Pralatrexate - Advanced Cancers, Solid Tumors | Phase 1 | Completed | M.D. Anderson Cancer Center | 72 | 2012-03-01 | 2016-07-04 |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients Pralatrexate Injection - Peripheral T-cell Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 21 | 2011-08-01 | 2021-11-19 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Nebraska | 29 | 2010-09-14 | 2023-12-26 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 35 | 2010-09-01 | 2017-12-13 |
Showing 20 of 34. Sign in to see all of them.
Lymphoma, T-Cell (11) · Lymphoma, T-Cell, Peripheral (11) · Recurrence (7) · Lymphoma (6) · Lymphoma, Large-Cell, Anaplastic (6) · Immunoblastic Lymphadenopathy (4) · Lymphoma, Non-Hodgkin (4) · Carcinoma, Non-Small-Cell Lung (3) · Hodgkin Disease (3) · Lymphoma, Follicular (3) · Lymphoma, T-Cell, Cutaneous (3) · Mycosis Fungoides (3) · Adenocarcinoma Of Esophagus (2) · Burkitt Lymphoma (2) · Enteropathy-Associated T-Cell Lymphoma (2)
Acrotech Biopharma Inc. (7) · Spectrum Pharmaceuticals, Inc (4) · University of Virginia (3) · City of Hope Medical Center (2) · Jennifer Amengual (2) · Memorial Sloan Kettering Cancer Center (2) · University of Nebraska (2) · Corvus Pharmaceuticals, Inc. (1) · Fred Hutchinson Cancer Center (1) · Kyowa Kirin, Inc. (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Millennium Pharmaceuticals, Inc. (1) · Mundipharma (China) Pharmaceutical Co. Ltd (1) · Ohio State University Comprehensive Cancer Center (1)
United States (29) · France (6) · Belgium (5) · Canada (4) · Italy (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Czechia (3) · Hungary (3) · Spain (3) · Argentina (2) · Israel (2) · New Zealand (2) · Peru (2)
Garry Weems, PharmD (2) · Michael Saunders, MD (2) · Owen O'Connor, MD, PhD (2) · Alex F Herrera (1) · Bor-Sheng Ko, PhD (1) · Christina Poh (1) · Craig Portell, MD (1) · Enrica Marchi, M.D., PhD (1) · Enrica Marchi, MD, PhD (1) · Garry Weems, Pharm.D. (1) · Jean Grem (1) · Jennifer Amengual, MD (1) · Jennifer E Amengual, MD (1) · Julie M Vose (1) · Lee M. Krug, MD (1)
PMID 12796370, PMID 19652067, PMID 26242208, PMID 27040320, PMID 29141948, PMID 30707661, PMID 30904980, PMID 38517235, PMID 40932107
2008 (1), P30CA016056 (1), P30CA033572 (1), P30CA036727 (1)